Serum macrophage inhibitory cytokine-1 serves as a novel diagnostic biomarker of early-stage colorectal cancer

References

• Awady, S.E., et al., 2009. Utility of serum preoperative carcinoembryonic antigen in colorectal cancer patients. Hepato-gastroenterology, 56 (90), 361–366.
   PubMedGoogle Scholar
• Bates, S.E., 1991. Clinical applications of serum tumor markers. Annals of internal medicine, 115 (8), 623–638.
   PubMed Web of Science ®Google Scholar
• Bootcov, M.R., et al., 1997. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proceedings of the national academy of sciences of the United States of America, 94 (21), 11514–11519.
   PubMed Web of Science ®Google Scholar
• Bray, F., et al., 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 68 (6):394–424.
   PubMed Web of Science ®Google Scholar
• Breit, S.N., et al., 2011. The TGF-β superfamily cytokine, MIC-1/GDF15: a pleotrophic cytokine with roles in inflammation, cancer and metabolism. Growth factors, 29 (5), 187–195.
   PubMed Web of Science ®Google Scholar
• Brown, D., et al., 2003. MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. Clinical cancer research, 9 (7), 2642–2650.
   PubMed Web of Science ®Google Scholar
• Brown, D.A., et al., 2002. Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study. Lancet, 359 (9324), 2159–2163.
   PubMed Web of Science ®Google Scholar
• Danta, M., et al., 2017. Macrophage inhibitory cytokine‐1/growth differentiation factor‐15 as a predictor of colonic neoplasia. Alimentary pharmacology & therapeutics, 46 (3), 347–354.
   PubMed Web of Science ®Google Scholar
• Duffy, M.J., 2001. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?. Clinical chemistry, 47 (4), 624–630.
   PubMed Web of Science ®Google Scholar
• Duffy, M.J., et al., 2007. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. European journal of cancer, 43 (9), 1348–1360.
   PubMed Web of Science ®Google Scholar
• Ganapathy-Kanniappan, S., and Geschwind, J.F.H., 2013. Tumor glycolysis as a target for cancer therapy: progress and prospects. Molecular cancer, 12 (1), 152.
   PubMedGoogle Scholar
• Gao, Y., et al., 2018. Evaluation of serum CEA, CA19-9, CA72-4, CA125 and ferritin as diagnostic markers and factors of clinical parameters for colorectal cancer. Scientific reports, 8 (1), 2732.
   PubMedGoogle Scholar
• García-Albéniz, X., et al., 2017. Effectiveness of screening colonoscopy to prevent colorectal cancer among medicare beneficiaries aged 70 to 79 years: a prospective observational study. Annals of internal medicine, 166 (1), 18–26.
   PubMed Web of Science ®Google Scholar
• Hardcastle, J.D., et al., 1996. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet, 348 (9040), 1472–1477.
   PubMed Web of Science ®Google Scholar
• Kazama, S., and Watanabe, T., 2014. Diagnosis of colorectal cancer by measurement of tumor markers. Nippon rinsho. Japanese journal of clinical medicine, 72 (1), 71–76.
   PubMedGoogle Scholar
• Komori, A., et al., 2017. Serum CA19-9 response is an early predictive marker of efficacy of regorafenib in refractory metastatic colorectal cancer. Oncology, 93 (5), 329–352.
   PubMed Web of Science ®Google Scholar
• Konishi, T., et al., 2018. Association of preoperative and postoperative serum carcinoembryonic antigen and colon cancer outcome. JAMA oncology, 4 (3), 309.
   PubMed Web of Science ®Google Scholar
• Koopmann, J., et al., 2004. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clinical cancer research, 10 (7), 2386–2392.
   PubMed Web of Science ®Google Scholar
• Kronborg, O., et al., 1996. Randomised study of screening for colorectal cancer with faecal-occult-blood test. The lancet, 348 (9040), 1467–1471.
   PubMed Web of Science ®Google Scholar
• Lin, J.K., et al., 2011. Early postoperative CEA level is a better prognostic indicator than is preoperative CEA level in predicting prognosis of patients with curable colorectal cancer. International journal of colorectal disease, 26 (9), 1135–1141.
   PubMed Web of Science ®Google Scholar
• Locker, G.Y., et al., 2006. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. Journal of clinical oncology, 24 (33), 5313–5327.
   PubMed Web of Science ®Google Scholar
• Luo, H., et al., 2020. Clinical significance and diagnostic value of serum NSE, CEA, CA199, CA125 and CA242 levels in colorectal cancer. Oncology letters, 20 (1), 742–750.
   PubMed Web of Science ®Google Scholar
• Mehta, R.S., et al., 2014. A prospective study of macrophage inhibitory cytokine-1 (MIC-1/GDF15) and risk of colorectal cancer. Journal of the national cancer institute, 106 (4), dju016.
   PubMedGoogle Scholar
• Nicolini, A., et al., 2010. Intensive risk-adjusted follow-up with the CEA, TPA, CA19.9, and CA72.4 tumor marker panel and abdominal ultrasonography to diagnose operable colorectal cancer recurrences: effect on survival. Archives of surgery, 145 (12), 1177–1183.
   PubMedGoogle Scholar
• Paralkar, V.M., et al., 1998. Cloning and characterization of a novel member of the transforming growth factor-beta/bone morphogenetic protein family. The journal of biological chemistry, 273 (22), 13760–13767.
   PubMed Web of Science ®Google Scholar
• Park, I.J., et al., 2009. Serum carcinoembryonic antigen monitoring after curative resection for colorectal cancer: clinical significance of the preoperative level. Annals of surgical oncology, 16 (11), 3087–3093.
   PubMed Web of Science ®Google Scholar
• Perkins, G.L., et al., 2003. Serum tumor markers. American family physician, 68 (6), 1075–1082.
   PubMed Web of Science ®Google Scholar
• Qiu, M., et al., 2015. Pattern of distant metastases in colorectal cancer: a SEER based study. Oncotarget, 6 (36), 38658–38666.
   PubMedGoogle Scholar
• Thomas, D.S., et al., 2015. Evaluation of serum CEA, CYFRA21-1 and CA125 for the early detection of colorectal cancer using longitudinal preclinical samples. British journal of cancer, 113 (2).
   Web of Science ®Google Scholar
• Tokunaga, R., et al., 2017. The utility of tumor marker combination, including serum P53 antibody, in colorectal cancer treatment. Surgery today, 47 (5), 636–637.
   PubMed Web of Science ®Google Scholar
• Vissers, P.A.J., et al., 2016. Prospectively measured lifestyle factors and BMI explain differences in health-related quality of life between colorectal cancer patients with and without comorbid diabetes. Supportive care in cancer, 24 (6), 2591–2601.
   PubMed Web of Science ®Google Scholar
• Vocka, M., et al., 2016. Growth/differentiation factor 15 (GDF-15) as new potential serum marker in patients with metastatic colorectal cancer. Cancer biomarkers, 1–6.
   Web of Science ®Google Scholar
• Wang, X.B., et al., 2014. Macrophage inhibitory factor 1 acts as a potential biomarker in patients with esophageal squamous cell carcinoma and is a target for antibody-based therapy. Cancer science, 105 (2), 176–185.
   PubMed Web of Science ®Google Scholar
• Wang, X., Baek, S.J., and Eling, T.E., 2013. The diverse roles of nonsteroidal anti-inflammatory drug activated gene (NAG-1/GDF15) in cancer. Biochemical pharmacology, 85 (5), 597–606.
   PubMed Web of Science ®Google Scholar
• Wang, X., et al., 2017. Circulating MIC-1/GDF15 is a complementary screening biomarker with CEA and correlates with liver metastasis and poor survival in colorectal cancer. Oncotarget, 8(15).
   Google Scholar